干扰素α对乙型肝炎病毒感染小鼠血清病毒标记物的影响*

doi:10.3969/j.issn.1672-5069.2017.04.026

Abstract

Zhou Yun, Li Sheng, Tang Zongsheng, et al.. Serum HBsAg and HBeAg changes in pCMV2/IFN-α4 plasmid-infected mice[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 483-485.

[1] Liaw YF,Chu CM. Hepatitis B virus infection. Lancet,2009,373（9663）:582-592.
[2] Yang PL,Althage A,Chung J,et al. Hydrodynamic injection of viral DNA:a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A,2002,99（21）:13825-13830.
[3] Huang LR,Wu HL,Chen PJ,et al. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A,2006,103（47）:17862-17867.
[4] Isaacs A, Lindenmann J. Virus interference. The interferon. Proc R Soc Lond B Biol Sci,1957,147（927）:258-267.
[5] Zoulim F,Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med,2015,5（4）:232-236.
[6] 康富标,孙殿兴,李东,等. 干扰素-α2b治疗非母婴传播HBeAg阳性慢性乙型肝炎患者疗效分析. 实用肝脏病杂志,2016,19（4）：471-473.
[7] 严鑫,钟锐华,刘锦红,等. HBV转基因小鼠体内淋巴细胞表型特点及干扰素α对其的影响. 南方医科大学学报,2016,36（6）：870-874.
[8] Snell LM, Brooks DG. New insights into type I interferon and the immunopathogenesis of persistent viral infections. Curr Opin Immunol,2015,34:91-98.
[9] Schreiber G,Piehler J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol,2015,36（3）:139-149.
[10] McNab F,Mayer-Barber K,Sher A,et al. Type I interferons in infectious disease. Nat Rev Immunol,2015,15（2）:87-103.
[11] Crouse J,Kalinke U,Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol,2015,15（4）: 231-242.
[12] Wilson EB,Yamada DH,Elsaesser H,et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science,2013,340（6129）:202-207.
[13] Teijaro JR,Ng C,Lee AM,et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science,2013,340（6129）:207-211.
[14] Hahm B,Trifilo MJ,Zuniga EI,et al. Viruses evade the immune system through type I interferon-mediated STAT2-dependent,but STAT1-independent,signaling. Immunity,2005,22（2）:247-257.
[15] Mayer-Barber KD,Andrade BB,Oland SD,et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature,2014,511（7507）:99-103.
[16] Cha L,Berry CM,Nolan D,et al. Interferon-alpha,immune activation and immune dysfunction in treated HIV infection. Clin Transl Immunology,2014,3（2）:e10.
[17] Osokine I,Snell LM,Cunningham CR,et al. Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proc Natl Acad Sci U S A,2014,111（20）:7409-7414.
[18] Thomson AW,Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol,2010,10（11）:753-766.
[19] Milich DR,McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science,1986,234（4782）:1398-1401.

Serum HBsAg and HBeAg changes in pCMV2/IFN-α4 plasmid-infected mice

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Zhang Xuan, Tang Xiaoyun, Tang Chunyin, et al. Effect of Chinese herbal medicine on intestinal microflora in mice with D-galactosamine/LPS-induced acute liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 478-481.